Herd immunity generated by the introduction of the 13-valent pneumococcal conjugate vaccine in the United States —  first in 2010 for children, then in 2012 for immunocompromised adults, in series with the 23-valent pneumococcal polysaccharide vaccine — has driven down the incidence of invasive pneumococcal disease, or IPD, in adults with and without underlying medical conditions, researchers reported.
In 2014, the CDC’s Advisory Committee on Immunization Practices (ACIP) recommended that all adults aged 65 years or older routinely receive the 13-valent pneumococcal

Source link